Alisol B NEW
| Price | $64 | $197 | $293 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-15 |
Product Details
| Product Name: Alisol B | CAS No.: 18649-93-9 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2026/07/15 |
Product Introduction
Bioactivity
| Name | Alisol B |
| Description | Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis. |
| In vitro | Alisol-B, a phyto-steroid from Alisma orientale Juzepczuk, exhibited inhibitory effects on osteoclastogenesis both in vitro and in vivo. Alisol-B did not affect the 1alpha,25(OH)(2)D(3)-induced expressions of RANKL, OPG and M-CSF mRNAs in osteoblasts, addition of alisol-B to co-cultures of mouse bone marrow cells and primary osteoblasts with 10(-8)M 1alpha,25(OH)(2)D(3) caused significant inhibition of osteoclastogenesis. The direct effects of alisol-B on osteoclast precursors. Alisol-B strongly inhibited RANKL-induced osteoclast formation when added during the early stage of cultures, suggesting that alisol-B acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways[1]. |
| Storage | Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (21.16 mM), Solution. DMSO : 250 mg/mL (528.88 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (21.16 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | RANKL | RANK | Inhibitor | inhibit | Alisol B |
| Inhibitors Related | 10-Hydroxydecanoic Acid | Phlorigidoside C | Amakusamine | Boldine | Anti-osteoporosis agent-11 | Pamidronate Disodium | Cyanidin Chloride | NFATc1-IN-1 | Pamidronic acid | Denosumab | (2S)-2'-Methoxykurarinone | Pamidronate disodium pentahydrate |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Traditional Chinese Medicine Monomer Library | Bioactive Compound Library | Selected Plant-Sourced Compound Library | Miao medicine Compound Library | Natural Product Library | Natural Product Library for HTS | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Food as Medicine Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00 |
VIP5Y
|
TargetMol Chemicals Inc.
|
2026-08-08 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-08-31 | ||
|
Shanghai Standard Technology Co., Ltd.
|
2023-02-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY